Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT2 | O60551 | 1/20 | 0.40 |
| ▸ | NMT1 | P30419 | 1/20 | 0.40 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.35 |
| ▸ | GLP1R | P43220 | 8/20 | 0.35 |
| ▸ | TLR2 | O60603 | 1/20 | 0.34 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | ALB | P02768 | 2/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.33 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18973016 | 0.92 | NMT1 (0.48) | NMT2NMT1NOD1GLP1RTLR2 | |
| SCHEMBL22692648 | 0.91 | NMT2 (0.40) | NMT2NMT1NOD1GLP1RTLR2 | |
| SCHEMBL22857340 | 0.90 | NMT2 (0.40) | NMT2NMT1NOD1GLP1RTLR2 | |
| SCHEMBL24119975 | 0.89 | NMT2 (0.46) | NMT2NMT1NOD1GLP1RTLR2 | |
| SCHEMBL23626256 | 0.89 | NMT2 (0.42) | NMT2NMT1NOD1GLP1RTLR2 | |
| SCHEMBL20053467 | 0.88 | NMT2 (0.41) | NMT2NMT1NOD1GLP1RTLR2 | |
| SCHEMBL18513360 | 0.87 | MEN1 (0.40) | NMT2NMT1NOD1NAMPTCNR1 | |
| SCHEMBL20099362 | 0.86 | NMT2 (0.53) | NMT2NMT1NOD1GLP1RTLR2 | |
| SCHEMBL18879491 | 0.84 | GLP1R (0.49) | NMT2NMT1NOD1GLP1RTLR2 | |
| SCHEMBL22692674 | 0.82 | NMT1 (0.52) | NMT2NMT1NOD1GLP1RTLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210087566-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN (a) EXPRESSION | IONIS PHARMACEUTICALS, INC. | 2021-03-25 | — | — | US | disclosed |
| US-20170145424-A1 | COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS | IONIS PHARMACEUTICALS, INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170043025-A1 | METHOD FOR SYNTHESIS OF REACTIVE CONJUGATE CLUSTERS | IONIS PHARMACEUTICALS, INC. (US) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087566-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN (a) EXPRESSION | APOB, APOL1, LDLR | NMT2 241/4885NMT1 247/4885NOD1 318/4885 |
| US-20170043025-A1 | METHOD FOR SYNTHESIS OF REACTIVE CONJUGATE CLUSTERS | ACOT7, COASY, LCAT | NMT2 25/4885NMT1 58/4885NOD1 4057/4885 |
| US-20170145424-A1 | COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS | SI, FABP2, GNE | NMT2 65/4885NMT1 63/4885NOD1 191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.